Abstract. Previous reports suggest that age-related lysosomal disturbances contribute to Alzheimer-type accumulations of protein species, blockage of axonal/dendritic transport, and synaptic decline. Here, we tested the hypothesis that lysosomal enzymes are upregulated as a compensatory response to pathogenic protein accumulation. In the hippocampal slice model, tau deposits and amyloidogenic fragments induced by the lysosomal inhibitor chloroquine were accompanied by disrupted microtubule integrity and by corresponding declines in postsynaptic glutamate receptors and the presynaptic marker synaptophysin. In the same slices, cathepsins B, D, and L, ␤-glucuronidase, and elastase were upregulated by 70% to 135%. To address whether this selective activation of the lysosomal system represents compensatory signaling, N-Cbz-L-phenylalanyl-L-alanyl-diazomethylketone (PADK) was used to enhance the lysosome response, generating 4-to 8-fold increases in lysosomal enzymes. PADK-mediated lysosomal modulation was stable for weeks while synaptic components remained normal. When PADK and chloroquine were co-infused, chloroquine no longer increased cellular tau levels. To assess pre-existing pathology, chloroquine was applied for 6 days after which its removal resulted in continued degeneration. In contrast, enhancing lysosomal activation by replacing chloroquine after 6 days with PADK led to clearance of accumulated protein species and restored microtubule integrity. Transport processes lost during chloroquine exposure were consequently re-established, resulting in marked recovery of synaptic components. These data indicate that compensatory activation of lysosomes follows protein accumulation events, and that lysosomal modulation represents a novel approach for treating Alzheimer disease and other protein deposition diseases.
INTRODUCTION
Proteins with a propensity to aggregate or oligomerize are thought to be causative factors in a wide range of neurodegenerative disorders. Among age-related protein deposition diseases, altered processing and toxic accumulation of proteins have been reported to involve disturbances in the endosomal-lysosomal system (1) . For example, several studies implicate lysosomal disruption in the development of amyloidogenic fragments (2-7) and tau deposits (8) (9) (10) (11) (12) within neurons. The Huntington disease huntingtin protein also may require lysosomal structures to form aggregates (13, 14) . It is not surprising then that several pathologic features of age-related disorders are induced by the suppression of lysosomal function (1) . Interestingly, many protein deposition disorders also exhibit activation of the lysosomal system, as evidenced by the appearance of numerous lysosomal vacuoles with increased enzyme content (3, (15) (16) (17) (18) (19) (20) (21) (22) . The Alzheimer A␤1-42 peptide of the amyloid precursor protein (APP) causes an enzymatic upregulation consistent with lysosomal activation (23) , and this occurs in conjunction with the peptide's facilitation of lysosomal damage, amyloidogenic processing (24) (25) (26) (27) , and associated synaptic decline (25) .
While elevated levels of lysosomes and their digestive enzymes are generally reflective of lysosomal disturbances, the role such increases play has been a subject of speculation. One idea is that protein accumulation events trigger the lysosomal activation response in order to slow the progressive neurodegeneration they elicit. The present study tested this idea.
Amplification of lysosomal hydrolases is a key indicator of lysosomal activation, and this type of cellular regulation may represent a compensatory response against age-related neurodegeneration as previously suggested (15, 16) . Lysosomal activation appears to be a response to protein deposition and synaptic pathology as found in brain tissue exposed to lysosomal enzyme inhibitors or to acidotropic compounds that disrupt lysosomal pH (9) . Such agents, indeed, have been used to induce age-related lysosomal dysfunction and to study the resultant neuropathogenesis (5, 6, (8) (9) (10) (11) (12) . These and other studies (23, 25) further support the idea that upregulation of appropriate lysosomal enzymes is driven by signaling events in an attempt to offset the consequences of abnormal protein accumulation. If lysosomal activation represents compensatory signaling, positive modulation of the lysosomal response should lead to protection against protein accumulation and the associated synaptic pathology.
Protein accumulation/aggregation is a common pathogenic mechanism among age-related disorders including Alzheimer disease (AD). Thus, the present study made use of a model system that can reproduce AD-related 452 BENDISKE AND BAHR J Neuropathol Exp Neurol, Vol 62, May, 2003 protein accumulations as well as progressive neurodegeneration (9, 12) . By experimentally inducing lysosomal dysfunction with chloroquine in hippocampal slice cultures, we were able to test the concept of compensatory activation of the lysosomal system. Of particular interest was the effect lysosomal activation has on cellular changes that lead to synaptopathogenesis in the slice cultures. Such changes appear to result in a dramatic decline in the number of synapses per neuron (1), a decline that is also evident in early-stage AD (28) . Biochemical and morphological indicators suggest that synapses are the initial target of Alzheimer-type pathogenesis (20, (29) (30) (31) (32) , especially in the hippocampus (33) (34) (35) . The hippocampal slice model exhibits a loss of postsynaptic glutamate receptors at the protein and message level (5, 12, 36) , similar to that found in the AD hippocampus and entorhinal cortex (37) (38) (39) (40) . The presynaptic marker synaptophysin also declines in the model, and its loss in hippocampus and other regions correlates with the degree of cognitive decline in AD (29, 41, 42) and occurs early in some transgenic models of the disease (43, 44) .
Using the slice model, we demonstrate here that lysosomal enzyme responses can be positively modulated to promote clearance of protein deposits and, in an associative manner, to restore cellular markers used to track chloroquine-induced synaptic decline. Recent findings suggest that protein accumulation blocks synaptic maintenance by disrupting microtubule-based transport, and that initial transport failure occurs before appreciable protein deposition (12) . Correspondingly, experiments in the present report show that restoration of transport mechanisms and reversal of synaptopathogenesis follows lysosomal modulation, thus supporting the hypothesis that lysosomal activation represents compensatory signaling against the AD-type pathogenic cascade.
MATERIALS AND METHODS

Antibodies and Chemicals
Monoclonal antibodies against synaptophysin, tau, and ␣-acetylated tubulin were obtained from Boehringer Mannheim (Indianapolis, IN) and ICN Biomedicals (Costa Mesa, CA). Antibodies to actin were obtained from Sigma Chemical Company (St. Louis, MO), antibodies to cathepsin B from Upstate Biotechnology (Lake Placid, NY), antibodies to cathepsins D, L, and S and ␤-glucuronidase from Cortex Biochem (San Leandro, CA), anti-elastase from Biodesign International (Saco, ME), PHF-1 antibodies against human paired helical filaments (PHFs) from ICN Biomedicals, and affinity-purified antibodies to proteasome 20S C2 subunit were from Affinity BioReagents (Golden, CO). Antibodies that recognize carboxyl-terminal fragments of APP were from Boehringer Mannheim. Affinitypurified antibodies to the AMPA receptor subunit GluR1 were prepared as previously described (45) . N-Cbz-L-phenylalanyl-L-alanyl-diazomethylketone (PADK), diazoacetyl-DL-2-aminohexanoic acid methyl ester, and glycyl-phenylalanyl-glycinealdehyde semicarbazone were obtained from Bachem (King of Prussia, PA). A␤1-42 and a scrambled version of the peptide were synthesized and characterized by electrospray mass spectroscopy (46) , obtained from Dr. Charles Glabe (University of California, Irvine). All other cell culture supplies, chloroquine, and horseradish peroxidase (HRP) were obtained from Sigma Chemical Company. Protease inhibitors were obtained from Boehringer Mannheim. Nitrocellulose immunoblotting paper was obtained from Osmonics (Westborough, MA). Alkaline phosphatase-conjugated and HRP-conjugated antibodies and substrate kits were from Bio-Rad Laboratories (Richmond, CA) and Vector Laboratories (Burlingame, CA). RNase Easy and RNase-free DNase kits were supplied by Quiagen (Valencia, CA).
Organotypic Hippocampal Slice Cultures
Sprague-Dawley rat litters (Charles River Laboratories, Wilmington, MA) were housed in accordance with guidelines from the National Institutes of Health. Animals 11 to 12 days postnatal were subjected to isoflurane anesthesia (Baxter, Deerfield, IL) and immediate decapitation. Transverse slices of hippocampus (400 m) were then quickly prepared, maintained on Millicell-CM inserts (Millipore Corporation, Bedford, MA), and periodically supplied with fresh media composed of 50% basal medium Eagle, 25% Earle's balanced salts, 25% horse serum, and defined supplements (5, 47) . Slices were maintained at 37ЊC with a 5% CO 2 -enriched atmosphere for 15 to 20 days before use in experiments. Synaptic function was assessed as previously described (5) .
Slice cultures were incubated with media containing vehicle, 60 M chloroquine, 17 M A␤ peptides, 1 to 10 M PADK, or combinations thereof. Treatments were staggered so that all slices were in culture for the same length of time. Chloroquine is a weak base that accumulates in lysosomes, leading to the disruption of protein degradation while having no direct effect on protein synthesis (5, 48, 49) . The chloroquine dose used was shown to influence lysosomal processes without affecting glycosylation, tyrosine sulfation, protein synthesis and secretion, or neuronal properties underlying synaptic waveform. Chloroquine produces a characteristic delayed effect on protein processing and synaptic composition, nearly identical to that produced by cathepsin inhibitors and by an ATPase blocker that disrupts lysosomal pH (5, 8, 9, 11) .
Immunoblot Analysis
Slices were removed with a soft brush and homogenized as samples of 6 to 8 slices each using ice-cold buffer containing 0.32 M sucrose, 5 mM HEPES (pH 7.4), 1 mM EDTA, 1 mM EGTA, 1 M okadaic acid, 10 nM calyculin A, and the protease inhibitors aprotinin, leupeptin, bestatin, E-64, pepstatin A (each at 2 g/mL), and 4-(2-aminoethyl)benzenesulfonyl fluoride (0.3 mM). Protein content was determined with BSA standards and equal aliquots of protein (80 g) were denatured in sample buffer for 5 min at 100ЊC, then separated by 4% to 16% SDS-PAGE and blotted to nitrocellulose. Blots were treated with primary antibodies overnight, and secondary antibody incubation utilized anti-IgG-alkaline phosphatase conjugates. Color development used the 5-bromo-4-chloro-3-indolyl phosphate/ nitroblue tetrazolium substrate system. The development of bands was terminated before maximal intensity was reached in order to ensure a linear relationship with increasing amount of sample protein. Immunoreactive bands were scanned at high resolution and assessed for integrated density with BIOQUANT software (R&M Biometrics, Nashville, TN). Prior to staining for tau immunoreactivity, blots were treated with alkaline phosphatase at a concentration of 0.1 units/mL.
Immunocytochemistry
The slices were rinsed with 0.1 M phosphate buffer, pH 7.4 (PB) and fixed for 2 h in PB containing 4% paraformaldehyde. Slices were cryoprotected and carefully removed from the insert, then sectioned at 20-m thickness. Sections were immunolabeled with PHF-1 antibodies using the avidin-biotin-peroxidase technique and 3,3Ј-diaminobenzidine as the chromogen. Image capture was made possible with the BIOQUANT image analysis system linked to an Olympus AX70 microscope.
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
Cultured slices were harvested, RNA isolated, and corresponding cDNA generated as previously described (12) . PCR was carried out using 200 ng cDNA in a total volume of 25 L containing 1ϫ PCR reaction buffer, 2.5 mM MgCl 2 , 0.2 mM dNTPs, 0.25 mM primers, and 1.25 U/L Taq DNA polymerase. Cathepsin D, GluR1, and house-keeping gene (HPRT) primers were designed according to GenBank sequences for the respective genes, and synthesized by the University of Connecticut Biotechnology Center. PCR products were electrophoretically separated on 2% agarose gels and their images captured using the Kodak EDAS120 system (Rochester, NY).
Transport Analysis
A small slurry was prepared with 20 mg of HRP in slice buffer containing 2 M sucrose. Using cultures on membrane inserts, HRP was administered to pyramidal neurons of control and treated hippocampal slices via a fine-tip electrode. After 2 h at 37ЊC, the treated slices were washed in PB and then fixed in cold PB containing 4% paraformaldehyde for 2 h. Slices were cryoprotected in a 20% sucrose solution, carefully removed from the inserts, and mounted on gelatin-coated slides. The slices were then stained for 5 to 10 min with 3-3Ј-diaminobenzidine, treated with ascending concentrations of ethanol and clearing agent, and coverslipped.
RESULTS
Hippocampal slice cultures were used since they possess native synaptic circuitries and exhibit cellular and synaptic changes consistent with early AD pathogenesis when treated with lysosomal disruptors (5, 24, 36) . The acidotropic compound chloroquine caused a steady decline in the presynaptic vesicle protein synaptophysin (Fig. 1a) and in a postsynaptic marker (Fig. 2b) , while other proteins remained the same (e.g. actin) or increased in concentration. Such synaptic decline is similar to that previously reported, and the selective reduction occurred over the same time period that the lysosomal inhibitor induced protein deposition, transport failure, and a corresponding reduction in evoked EPSPs (5, 12) . Associated with the reduced expression of synaptic proteins was the upregulation of the lysosomal hydrolase cathepsin B (Fig. 1a) ; a similar response was expressed by related enzymes cathepsins D and L (Table; Fig. 1a ). Besides members of the cathepsin family of hydrolases, other lysosomal enzymes were selectively upregulated, including Slices were treated with chloroquine alone for 6 days or followed by PADK modulation (3 M), then compared to control slices after assessing for enzyme content via immunoblot using selective antibodies. n.d., not determined.
␤-glucuronidase and elastase (Table) . While chloroquineinduced lysosomal activation consisted of increases in nearly all enzymes measured, there was an almost 50% decrease in cathepsin S.
As with the lysosomal inhibitor chloroquine, a similar correspondence between synaptic decline and lysosomal activation was found when the slice cultures were treated with A␤1-42 (Fig. 1b) , the ␤-amyloid peptide shown to be taken up by neurons and causing lysosomal disruption (25) (26) (27) . The cathepsin D hydrolase was increased by 47% Ϯ 5% and synaptophysin was reduced by 54% Ϯ 7% (mean Ϯ SEM, p Ͻ 0.01) as compared to levels in slices treated for 10 to 17 days with a scrambled version of the 42-residue sequence. Matching previous results with chloroquine treatment (5), the synaptic decline produced by A␤1-42 was also associated with a 46% decrease in EPSP amplitude measured in the stratum radiatum of CA1a (p Ͻ 0.01).
Similar to the lysosome responses induced by the broad lysosomal inhibitor chloroquine and A␤1-42, a specific cathepsin inhibitor also caused hydrolase upregulation. N-Cbz-L-phenylalanyl-L-alanyl-diazomethylketone (PADK) selectively inhibits cathepsins B and L, but was found to cause increases in several lysosomal enzymes (Table) . A high concentration of PADK (200 M) over a 5-day period has been previously shown to induce lysosomal activation (9) as well as the same level of synaptic decline as elicited by chloroquine (5). However, application of much lower concentrations of PADK (1-10 M) for 20 days or more did not trigger deficits in the postsynaptic AMPA receptor subunit GluR1 (Fig. 2a) . The glutamate receptor subunit and the presynaptic marker remained at stable concentrations in the PADK-treated slices (see blots in Fig. 2 ), while cathepsin levels increased 4-to 5-fold. The synaptic maintenance is in striking contrast to the synaptic decline associated with chloroquine-mediated lysosomal activation (Fig. 2b) . The lysosomal response produced by low-level PADK was more pronounced than that expressed by chloroquine-treated slice cultures. In only a few days, appropriate concentrations of PADK elicited modulatory action that generated 2-to 8-fold increases in lysosomal enzymes over the level of activation found after 6 days of chloroquine treatment ( Fig. 3; Table) . Moreover, PADK modulation upregulated cathepsin S, which was reduced in concentration by chloroquine. Note that the selective modulation of the lysosomal system by PADK was not influenced by prior exposure of slices to chloroquine.
Having demonstrated the ability to induce positive lysosomal modulation without affecting synaptic maintenance, we addressed whether lysosomal activation represents a compensatory response. We first examined the effects of the lysosomal modulator PADK on the early induction of phosphorylated tau species (12) . The induction of tau was 2-to 3-fold resulting from 3 days of chloroquine treatment (Fig. 4a; compare CQN sample to control lane). Interestingly, when chloroquine was infused together with PADK for the same time period, the chloroquine exposure no longer was associated with increased levels of the 55-to 69-kDa tau isoforms (rightmost lane). The same immunoblot sample exhibited a 3-to 4-fold increase in cathepsin immunoreactivity as compared to the nontreated control sample. It is important to note that the tau isoforms as well as actin protein levels were unchanged in slices treated with PADK alone for 3 days and for extended time periods of Ն20 days (first lane). Thus, PADK modulation selectively enhances the cellular content of lysosomal enzymes and promotes the stable maintenance of microtubule-binding proteins and other structural components.
Next, lysosomal function was disrupted prior to PADK treatment in order to examine the modulator's effects on pre-existing protein deposits and associated synaptopathogenesis. Chloroquine was applied to slice cultures for 6 days causing intraneuronal deposition of PHF-immunopositive material, an increase in carboxylterminal fragments of APP, as well as a gradual loss of synaptic components as previously reported (5, 12) . In spite of removing chloroquine from the media after the 6-day exposure, protein accumulation in pyramidal neurons persisted and appeared unchanged ( Fig. 5b ; control in Fig. 5a ), and levels of the GluR1 subunit continued to decline (Fig. 6a and open triangles in Fig.  6c ). In contrast, replacing chloroquine with PADK after the sixth day of treatment led to a marked reduction in APP fragments (Fig. 4b) and evident clearance of the polar deposits of PHF material (Fig. 5c) . No polar deposition was produced by a 9-day treatment with PADK alone.
Corresponding with PADK-mediated protein clearance was a marked recovery of the GluR1 postsynaptic marker (see closed triangles in Fig. 6c ; p Ͻ 0.00001, 2-way AN-OVA). PADK modulation caused significant recovery of the presynaptic protein synaptophysin as well. Such synaptic repair also was observed a week after the chloroquine exposure, the longest time point tested. Other cathepsin antagonists elicited similar neuroprotective lysosomal modulation. A specific inhibitor of cathepsin D, diazoacetyl-DL-2-aminohexanoic acid methyl ester (1 M), and the cathepsin B inhibitor glycyl-phenylalanylglycine-aldehyde semicarbazone (30 M) produced as much as 2-fold increases in cathepsin D and other cathepsins, as well as a corresponding 24% to 42% recovery of synaptic markers following the 6-day exposure to chloroquine (p Ͻ 0.01).
The PADK-induced synaptic recovery shown in Figure  6c was observed across 17 separate groups of slices. The slice samples exhibiting up to 71% restoration of synaptic markers expressed pronounced upregulation of lysosomal enzymes, including a 6-to 8-fold increase in cathepsin B as compared to chloroquine-treated slices without PADK modulation (Table) . Elastase was enhanced by a smaller 40% to 80% during lysosomal modulation. The slices then were harvested in groups of 6 to 8 and prepared for immunoblot analysis. The blot was treated with alkaline phosphatase prior to staining the 55-to 69-kDa tau isoforms with the tau-1 monoclonal antibody. The isoforms were increased 2-to 3-fold only in those slices treated with chloroquine alone. b: Untreated slices (first lane) and slices exposed to chloroquine for 6 days followed by 2 days of recovery without (second lane) or with PADK (third lane) were assessed by immunoblot, using antibodies that recognize 20-to 30-kDa carboxyl-terminal fragments of APP. Actin was assessed on the same blots.
Fig. 5.
Clearance of chloroquine-induced deposits follows lysosomal modulation. After 6 days of chloroquine exposure, the lysosomal disruptor was removed from the culture media and the slices were allowed to recover for 2 days in the absence (b) or presence (c) of 3 M PADK. Along with a nontreated control group (a), the hippocampal slices were harvested, fixed, and stained with PHF-1 antibodies in order to label intracellular deposits in CA1 pyramidal neurons (b, arrows). Deposit-free neurons are evident (c), as well as signs of partial clearance (arrowhead) and unchanged polar deposition (arrow). Abbreviations: sp, stratum pyramidale; sr, stratum radiatum. Scale bar ϭ 20 m.
produced by lysosomal processing. The correspondence between PADK-mediated lysosomal activation and synaptic recovery was evident not only at the protein level but at the message level as well. As shown by RT-PCR samples in Figure 6b , chloroquine-induced lysosomal dysfunction led to a small 35% increase in cathepsin D message and reduced expression of the GluR1 gene (middle lane as compared to control in the first lane). Positive lysosomal modulation by PADK, on the other hand, enhanced cathepsin D expression by 6-fold and restored the GluR1 message level to that found in control tissue (third lane in Fig. 6b) .
The collapse of microtubule integrity and disruption of somatofugal transport have been implicated in AD-type synaptopathogenic cascades (12, 50) . We tested if either of these cellular changes were affected by lysosomal activation, thereby facilitating synaptic recovery. We previously reported that lysosomal dysfunction in the slice model causes gradual protein deposition, a corresponding decline in acetylated tubulin (Ac-TN; a marker of stable microtubules), and, as shown here (Fig. 8) , the gradual loss of transport capability. None of these events occurred following PADK modulation alone for 6 days. We used acetylated tubulin as an indicator of microtubule integrity and found that it was reduced by 81% Ϯ 7% when measured 2 days after the chloroquine treatment was terminated (Fig. 6a) ; total tubulin levels were unchanged. HRP was applied to zones of the stratum pyramidale and neurons were allowed to internalize and transport the HRP for 2 h. Apical dendrites were assessed for peroxidase activity and blind scoring categorized the slices as good, fair, or poor, based on the number of neurites exhibiting transport and the extent of such transport.
Thus, distinct microtubule changes were elicited in the same slice samples exhibiting pronounced synaptopathogenesis. When PADK was administered after the chloroquine treatment, acetylated tubulin was gradually restored to levels similar to those found in control slices (2 rightmost lanes in Fig. 6a ), closely correlating with the recovery of synaptic components.
PADK's positive effect on microtubule integrity was associated with restored transport as part of the modulator's neuroprotective action. After the 2 days of PADK modulation, HRP applied to pyramidal neurons was found to be transported throughout an elaborate array of dendrites (Fig. 9c) in a manner that approximated the HRP distribution observed in control tissue (Fig. 9a) . Conversely, slices without PADK treatment exhibited no evidence of transport recovery 2 days after terminating the chloroquine exposure period (Fig. 9b) , a result consistent with the continued decline of synaptic markers seen in Figure 6c . Blind scoring of transport capability in 156 slice cultures confirmed the restorative effect on transport by PADK (Fig. 9d) .
DISCUSSION
The present study shows that activation of the lysosomal system is triggered during episodes of protein accumulation. Upon potentiation of the lysosomal response, a correspondence between the clearance of protein deposits and synaptic recovery occurred. The current results, thereby, further establish a strong inverse relationship between abnormal protein accumulation and synaptic maintenance. They also indicate that lysosomal activation represents compensatory signaling. Thus, lysosomal dysfunction not only promotes a deleterious cascade leading to synaptic decline; it also activates a compensatory response capable of protecting synapses.
Enzyme upregulation was elicited by experimentally inducing lysosomal disruption with the lysosomotropic agent chloroquine. The changes in lysosomal enzymes are similar to those identified in Alzheimer tissue (3, (15) (16) (17) (18) (19) (20) , perhaps in response to protein accumulation as in the slice model. Such evidence of a compensatory response induced by lysosomal abnormalities suggests that the brain is not merely the passive recipient of neurological insults. Lysosomal dysfunction is an age-related alteration (51, 52) , contributing to protein accumulation events in potentially many ways thereby establishing aging as a primary risk factor for neurodegenerative disorders (1). Evidence exists that indicates lysosomal responses are active in the aging brain and during the early 459 LYSOSOMAL MODULATION REVERSES SYNAPTOPATHOGENESIS Fig. 9 . Lysosomal modulation promotes the recovery of transport capability in hippocampal pyramidal neurons. After 6 days of lysosomal disruption, the chloroquine was removed from the media (b) or replaced with PADK (c) for a 2-day recovery period. In parallel with nontreated control tissue (a), HRP was applied to several zones of the stratum pyramidale to assess transport as in Figure 8 . The cultures were stained for peroxidase activity and their apical dendrites viewed by dark-field microscopy (viewfield width: 100 m). Transport was assessed in the 3 treatment groups (52 slices each) by 2 independent scorers in a blind manner (d).
2 analysis: 2 ϭ 58.9, p Ͻ 0.0001 across all 3 treatment groups; p Ͻ 0.0001 between nontreated controls vs chloroquine-treated slices without lysosomal modulation (CQN); p Ͻ 0.0001 between the CQN group of slices vs slices that also received lysosomal modulator (CQNϩPADK); no significant difference was found between the CQNϩPADK group and control cultures. stages of age-related disorders (15, 16, 18, 20) , possibly masking many of the symptoms until they can appear later. The gradual decay of synaptic composition and function in the slice model, as well as the long duration of AD, may be indicative of a prolonged struggle between protein accumulation events and compensatory responses.
Surprisingly, we found that the enzyme regulation events following a lysosomal disturbance are accessible to modulation. The modulating agent PADK allowed the lysosomal activation response to be enhanced in a controlled, nonpathogenic manner. Treatment with PADK greatly upregulated lysosomal enzymes and promoted the stable maintenance of cellular and synaptic components. Increasing cellular levels of lysosomal enzymes is also a potential therapeutic strategy to overcome the abnormal accumulations in neurodegenerative lysosomal storage diseases (53) . Upregulation of appropriate proteases may be part of a feedback system that keeps in check any buildup of modified of misfolded protein species. While chloroquine affects many pH-dependent hydrolases, PADK elicits a more pronounced lysosomal response via the mild and selective inhibition of cathepsins B and L. Thus, it may be undigested substrates of cathepsins B and L that are monitored, and their buildup that greatly influences the expression systems controlling lysosomal enzymes.
The compensatory lysosomal response involves the upregulation of at least the aspartic acid protease cathepsin D, the cysteine proteases cathepsins B and L, and possibly ␤-glucuronidase. Interestingly, ␤-glucuronidase is among the endosomal-lysosomal components highly expressed in A␤-resistant neuronal cell lines, thus implicating it in neuronal survival during pathogenic A␤ accumulation (54) . While the largest increases were expressed by cathepsins, the cysteine protease cathepsin S was reduced by the chloroquine treatment and positive lysosomal modulation only moderately enhanced its expression level. Such downregulation may be part of compensatory signaling since cathepsin S is capable of generating A␤ variants under certain conditions (55); however, there are indications of increased cathepsin S in AD and Down syndrome (21) . Cathepsins B, D, and L exhibited pronounced upregulation following chloroquine exposure and during PADK-mediated lysosomal modulation. This corresponds with the fact that these cathepsins are appropriately positioned for early repair responses. The enzymes are highly expressed in brain regions that are vulnerable to age-related diseases and that contain the highest amounts of APP (16, 56) . In addition, cathepsin D has been suggested to reduce A␤ secretion (55) and degrade tau (57) (58) (59) . Upregulation of cathepsin D occurs before overt cellular damage in neuronal populations targeted by AD as well as in animal models of neurodegeneration (7, 15, 16, 60) . It is noteworthy that cathepsin regulation is not restricted to episodes of lysosomal stress or age-related diseases. There are examples of normal biological processes where select proteases are upregulated, including members of the cathepsin family (61, 62) . Most interestingly, transcriptional activation of the cathepsin D gene is mediated by 17␤-estradiol (62), a hormone shown to accelerate APP trafficking, reduce A␤ generation, and reduce the risk of AD in postmenopausal women (63) (64) (65) (66) . Together with the current results, cathepsins, particularly the B, D, and L types, appear to be key components of neuroprotective lysosomal activation.
Lysosomal activation occurred in response to pathogenic protein accumulation. Chloroquine-mediated accumulation of proteins and protein fragments is indicative of altered trafficking and/or metabolism in the hippocampal slice model, similar to events associated with many age-related diseases. Such accumulations led to the disruption of microtubule integrity and the loss of microtubule-based transport processes necessary for synaptic maintenance. We recently proposed that these events make up a synaptopathogenic cascade (12) . Accordingly, compensatory signaling that affects one element of the cascade would also affect remaining downstream elements. As reported here, positive modulation of the lysosomal response promotes both the clearance of protein deposits and the recovery of synaptic composition. Thus, there is a clear connection between the first and last elements of the pathogenic cascade. As previously shown in the slice model, early protein accumulations were followed by the formation of intracellular deposits (1, 5, 12) . PHF-type deposition was composed of phosphorylated tau species that are well-known markers of the aged brain and AD (67) (68) (69) . Upon terminating chloroquine-induced lysosomal disruption, protein deposits and synaptic decline persisted. The intensity and frequency of PHF-immunopositive deposits remained stable or increased during the postinsult period, and synaptic markers continued to decline. Although insufficient to protect synapses, a strong link between synaptic decline and lysosomal activation was evident, similar to that found in AD neurons containing tau deposits (20, 35) . Enhancing the level of lysosomal activation led to clearance of protein accumulations and the return of synaptic maintenance. The clearance of polar tau deposits by lysosomal modulation is consistent with reports suggesting that tau degradation occurs in lysosomal compartments (9, 12, 70, 71) . The upregulation of lysosomal enzymes perhaps restores the ability of lysosomes to process modified and misfolded proteins, as evidenced by the reduction of tau species to normal levels.
Microtubule integrity also was rescued by enhancing the lysosomal activation response. The connection between microtubule destabilization and synaptic decline was indicated by the corresponding reduction in tubulin acetylation, a post-translational modification that provides a marker for microtubule stability (72) . Decreases in acetylated tubulin and increases in tubulin fragmentation have been previously shown to correlate with the degree of synaptic decline (12) . In addition, AD-related protein deposition events are thought to be involved in the disruption of microtubule integrity (12, 73) . In the slice model, persistent intracellular deposits and reduced acetylated tubulin levels occurred together. Interestingly, the opposite trend transpired during PADK-mediated lysosomal modulation, causing tubulin acetylation to be restored to a level similar to that expressed by nontreated control slices.
Stable microtubules are essential for transport mechanisms that support synapses. Thus, restoration of microtubule integrity is not only a consequence of lysosomal modulation but also a key factor in synapse recovery. As shown, microtubule destabilization and somatofugal transport failure were found associated during periods when protein deposits and synaptic decline persisted. Intraneuronal deposits have been linked to the disruption of transport mechanisms, thereby cutting off protein delivery and leading to downregulated expression of affected proteins (5, 12, 20) . A previous report indicates that initial transport failure occurs prior to overt protein deposition (12) . In the present study, lysosomal modulator applied after several days of lysosomal dysfunction induced both synaptic recovery and restoration of transport. Thus, neurons with severe intracellular deposits and near complete transport failure are capable of expressing synaptic recovery upon activation of appropriate compensatory signaling. Along with recent findings (74), the results also indicate that the deleterious effects of protein deposition on synaptic integrity are not permanent.
The slice model is a valuable tool for studying synaptic pathology because it exhibits gradual degeneration of nerve terminals, synonymous to that which is thought to occur during the initial stages of AD. As shown here and previously (5, 12) , lysosomal dysfunction causes a decline in synaptic proteins and their mRNAs, correlating with the degree of intracellular deposition. Such a correlation is similar to that evident in neurons of AD brains (20, 35) . Synaptic decline, in fact, is a prominent feature of Alzheimer brains, and the degree of cognitive impairment is more highly correlated with synaptic deterioration than with other pathological features. By clearing protein deposits and re-establishing microtubule-based mechanisms, PADK restored synaptic integrity as evidenced by the marked recovery of pre-and postsynaptic markers. The fact that lysosomal modulation rescues synapse maintenance in the face of acute protein accumulation leads to the idea that the lysosomal system can be exploited to treat protein deposition diseases. The need for early clearance of accumulated protein species is an increasingly recognized theme among a diverse group of protein deposition disorders, thus, implicating lysosomal modulation as a common therapeutic approach.
Lysosomal activation may be among many examples of compensatory systems that are activated in response to disease states or toxin exposure. The presence of compensatory signaling, although at insufficient levels to prevent gradual synaptic deterioration, possibly allows cellular repair to require only modest intervention of the pathogenic cascade. It is important to note that even trace levels of synaptic recovery may lead to progressive cellular recuperation facilitated by the restored neurotransmission and associated signaling events. Particularly in the hippocampus, glutamatergic transmission is vital for synaptic and cellular maintenance (36, 75, 76) . Thus, modest levels of recovery might reinstate synaptic signaling to a sufficient degree to activate compensatory pathways, thereby slowing degenerative processes and altering the balance between pathogenesis and repair.
